Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Roche Holding Ltd. : Roche purchases shares in tender offer for Anadys Pharmaceuticals

share with twitter share with LinkedIn share with facebook
share via e-mail
11/23/2011 | 07:15am CET

Basel, 23 November 2011

Roche purchases shares in tender offer for Anadys Pharmaceuticals

Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) at $3.70 per share in cash.

As of the expiration of the tender offer, a total of approximately 54,532,568 shares of Anadys common stock were tendered and not withdrawn (including approximately 2,345,764  shares tendered by delivery of notices of guaranteed delivery), representing approximately 94% of Anadys's outstanding shares.

Roche intends to complete the acquisition of Anadys through a short-form merger without a vote or meeting of Anadys's shareholders. In the merger, all shares of Anadys not owned by Anadys, Roche or their respective wholly owned subsidiaries (other than shares as to which appraisal rights are validly exercised) will be converted into the right to receive the same cash consideration per share as was paid in the tender offer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical Co., Ltd., Japan. For more information: www.roche.com.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements, including statements regarding the expected consummation of the acquisition, which involves a number of risks and uncertainties including the satisfaction of closing conditions for the acquisition such as regulatory approval for the transaction, the tender of a majority of the outstanding shares of common stock of Anadys and the possibility that the transaction will not be completed. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from any future statements. We generally identify these statements by words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," "should," "estimate," "predict," "potential," "continue," or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. The information contained in this press release is as of November 23, 2011. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Important Additional Information

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Anadys common stock. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) filed by Roche with the Securities and Exchange Commission (the "SEC") on October 25, 2011 [and subsequently amended]. These materials, as they may be further amended from time to time, contain important information, including the terms and conditions of the offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and Anadys's stockholders can obtain a free copy of these materials and other documents filed by Roche with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer materials may also be obtained for free by contacting the information agent for the tender offer, Mackenzie Partners at (212) 929-5500 (call collect) or (800) 322-2885 (toll-free) (USA).

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
11:11aGlaxoSmithKline prescribes commercial reboot for pharma division
10:22aGlaxoSmithKline prescribes commercial reboot for pharma division
03/20Roche says Tecentriq, chemo cut risk of death in type of lung cancer
03/20ROCHE : Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizu..
03/19GLOBAL ARTIFICIAL INTELLIGENCE AND A : Global Artificial Intelligence And Advanc..
03/19PTC THERAPEUTICS : FIREFISH Transitions into Pivotal Phase
03/19FOUNDATION MEDICINE : CMS issues final coverage decision for NGS cancer tests
03/17ROCHE : Federal Contracts Awarded to Companies in Indiana (March 17)
03/17ROCHE : Federal Contracts Awarded by Federal Agencies in North Dakota (March 17)
03/16KNOW ABOUT CERVICAL CANCER MARKET IN : New Research: Cervical Cancer Market &nda..
More news
News from SeekingAlpha
08:00aYOUR DAILY PHARMA SCOOP : Arena Soars, Roche Data, GlaxoSmithKline Commences Stu.. 
03/20FDA Ad Com tomorrow for reclassification of certain laboratory devices used i.. 
03/20Unum Therapeutics Updates Proposed IPO Terms 
03/20Roche's Tecentriq successful in late-stage study in first-line NSCLC 
03/18ETF MONTH #4 : Developed Markets (Ex-North America) With EFA. But Is There A Bet.. 
Financials ( CHF)
Sales 2018 55 276 M
EBIT 2018 19 152 M
Net income 2018 11 857 M
Debt 2018 4 190 M
Yield 2018 3,95%
P/E ratio 2018 15,29
P/E ratio 2019 14,54
EV / Sales 2018 3,52x
EV / Sales 2019 3,34x
Capitalization 190 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 266  CHF
Spread / Average Target 21%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-10.99%199 363
JOHNSON & JOHNSON-6.79%349 387
PFIZER1.55%216 268
NOVARTIS-5.90%213 387
MERCK AND COMPANY-2.90%147 293
AMGEN4.68%131 539